WAHL BRYAN (General Counsel) sold 15.8% of their position (9.69K shares) of TARSUS PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $463.8K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 3/20/2025ACC: 0001819790-25-000057
Officer· General Counsel
Since Jan 2021
-9.69K
Net shares
Net seller
$463.8K
Total sold
3
Open market trades
0B · 3S
3
Total transactions
9.69K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
−3.34K
Price / share
$46.29
Trade value
$154.65K
% of position
5.4%
3/18/2025
61.40K→58.06K
Common Stock
Direct
Shares
−3.26K
Price / share
$47.40
Trade value
$154.57K
% of position
5.6%
3/19/2025
58.06K→54.80K
Common Stock
Direct
Shares
−3.08K
Price / share
$50.11
Trade value
$154.54K
% of position
5.6%
3/20/2025
54.80K→51.71K
Total
Net shares
−9.69K
Net value
-$463.77K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/18/2025 | S · Sale | −3.34K | $46.29 | $154.65K | 5.4% | 61.40K | 58.06K |
| Common Stock Direct | 3/19/2025 | S · Sale | −3.26K | $47.40 | $154.57K | 5.6% | 58.06K | 54.80K |
| Common Stock Direct | 3/20/2025 | S · Sale | −3.08K | $50.11 | $154.54K | 5.6% | 54.80K | 51.71K |
| Total | −9.69K | -$463.77K | ||||||
Derivative Transactions0
No derivative transactions reported